A report using global data mining and multiple reaction monitoring method suggested that ANLN may serve as a potential biomarker when combined with filamin-B (FLNB) to improve the discrimination of HCC patients from the healthy controls [24]. The gene discussed is ANLN; the disease is hepatocellular carcinoma.